{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:12:53Z","timestamp":1789701173822,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T00:00:00Z","timestamp":1421193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T00:00:00Z","timestamp":1421193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/srep07771","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T10:15:40Z","timestamp":1421230540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Co-immunization with DNA and protein mixture: A safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice"],"prefix":"10.1038","volume":"5","author":[{"given":"Si","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DanYang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Zhou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,14]]},"reference":[{"key":"BFsrep07771_CR1","first-page":"108","volume":"6","author":"CA Lemere","year":"2010","unstructured":"Lemere, C. A. & Masliah, E. Can Alzheimer disease be prevented by amyloid-\u03b2 immunotherapy? Nat Rev Neurosci 6, 108\u2013119 (2010).","journal-title":"Nat Rev Neurosci"},{"key":"BFsrep07771_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2174\/187152710791012008","volume":"9","author":"T Town","year":"2010","unstructured":"Town, T. Inflammation, Immunity and Alzheimer's Disease. CNS Neurol Disord Drug Targets 9, 129\u2013131 (2010).","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"BFsrep07771_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/msj.20156","volume":"77","author":"T Wisniewski","year":"2010","unstructured":"Wisniewski, T. & Boutajangout, A. Vaccination as a therapeutic approach for Alzheimer's disease. Mt Sinai J Med 77, 17\u201331 (2010).","journal-title":"Mt Sinai J Med"},{"key":"BFsrep07771_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353\u2013356 (2002).","journal-title":"Science"},{"key":"BFsrep07771_CR5","first-page":"54","volume":"269","author":"D Morgan","year":"2011","unstructured":"Morgan, D. Immunotherapy for Alzheimer's Disease. J Gen Intern Med 269, 54\u201363 (2011).","journal-title":"J Gen Intern Med"},{"key":"BFsrep07771_CR6","doi-asserted-by":"publisher","first-page":"9810","DOI":"10.1073\/pnas.0703137104","volume":"104","author":"A Muhs","year":"2007","unstructured":"Muhs, A. et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A 104, 9810\u20139815 (2007).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFsrep07771_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.2174\/187152709787847298","volume":"8","author":"A Ghochikyan","year":"2009","unstructured":"Ghochikyan, A. Rationale for peptide and DNA based epitope vaccines for Alzheimer's Disease immunotherapy. CNS Neurol Disord Drug Targets 8, 128\u2013146 (2009).","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"BFsrep07771_CR8","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.vaccine.2011.12.136","volume":"30","author":"PB Olkhanud","year":"2012","unstructured":"Olkhanud, P. B. et al. DNA immunization with HBsAg-based particles expressing a B cell epitope of amyloid \u03b2-peptide attenuates disease progression and prolongs survival in a mouse model of Alzheimer's disease. Vaccine 30, 1650\u20131658 (2012).","journal-title":"Vaccine"},{"key":"BFsrep07771_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/npp.2011.211","volume":"37","author":"AV Savonenko","year":"2011","unstructured":"Savonenko, A. V. et al. Alzheimer's therapeutics: translation of preclinical science to clinical drug development. Neuropsychopharmacol 37, 261\u2013277 (2011).","journal-title":"Neuropsychopharmacol"},{"key":"BFsrep07771_CR10","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/35050116","volume":"408","author":"D Morgan","year":"2000","unstructured":"Morgan, D. et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982\u2013985 (2000).","journal-title":"Nature"},{"key":"BFsrep07771_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0896-6273(03)00294-0","volume":"38","author":"C Hock","year":"2003","unstructured":"Hock, C. et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's Disease. Neuron 38, 547\u2013554 (2003).","journal-title":"Neuron"},{"key":"BFsrep07771_CR12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard, F. et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916\u2013919 (2000).","journal-title":"Nat Med"},{"key":"BFsrep07771_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo, J. M. et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 46\u201354 (2003).","journal-title":"Neurology"},{"key":"BFsrep07771_CR14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/intimm\/dxg049","volume":"15","author":"DH Cribbs","year":"2003","unstructured":"Cribbs, D. H. et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15, 505\u2013514 (2003).","journal-title":"Int Immunol"},{"key":"BFsrep07771_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.neurobiolaging.2004.02.005","volume":"25","author":"D Morgan","year":"2004","unstructured":"Morgan, D. & Gitter, B. D. Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease. Neurobiol Aging 25, 605\u2013608 (2004).","journal-title":"Neurobiol Aging"},{"key":"BFsrep07771_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1471-4159.2011.07458.x","volume":"120","author":"J Delrieu","year":"2012","unstructured":"Delrieu, J., Ousset, P. J., Caillaud, C. & Vellas, B. Clinical trials in Alzheimer's disease:immunotherapy approaches. J Neurochem 120, 186\u2013193 (2012).","journal-title":"J Neurochem"},{"key":"BFsrep07771_CR17","doi-asserted-by":"publisher","first-page":"11436","DOI":"10.1074\/jbc.M609690200","volume":"282","author":"N Moretto","year":"2007","unstructured":"Moretto, N. et al. Conformation-sensitive Antibodies against Alzheimer Amyloid-\u03b2 by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide. J Biol Chem 282, 11436\u201311445 (2007).","journal-title":"J Biol Chem"},{"key":"BFsrep07771_CR18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1074-7613(94)80017-0","volume":"1","author":"J Alexander","year":"1994","unstructured":"Alexander, J. et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-lockbing peptides. Immunity 1, 751\u2013761 (1994).","journal-title":"Immunity"},{"key":"BFsrep07771_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/BF02788751","volume":"18","author":"J Alexander","year":"1998","unstructured":"Alexander, J. et al. The Optimization of Helper T Lymphocyte (HTL) Function in Vaccine Development. Immunol Res 18, 79\u201392 (1998).","journal-title":"Immunol Res"},{"key":"BFsrep07771_CR20","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.4049\/jimmunol.164.3.1625","volume":"164","author":"J Alexander","year":"2000","unstructured":"Alexander, J. et al. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol 164, 1625\u20131633 (2000).","journal-title":"J Immunol"},{"key":"BFsrep07771_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clim.2013.05.016","volume":"149","author":"YZ Yu","year":"2013","unstructured":"Yu, Y. Z. et al. Effective DNA epitope chimeric vaccines for Alzheimer's disease using a toxin-derived carrier protein as a molecular adjuvant. Clin Immunol 149, 11\u201324 (2013).","journal-title":"Clin Immunol"},{"key":"BFsrep07771_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3233\/JAD-132177","volume":"41","author":"YZ Yu","year":"2014","unstructured":"Yu, Y. Z. et al. Strikingly Reduced Amyloid burden and improved behavioral performance in Alzheimer's Disease mice immunized with recombinant chimeric vaccines by hexavalent foldable A\u03b21-15 fused to toxin-derived carrier proteins. J Alzheimers Dis 41, 243\u2013260 (2014).","journal-title":"J Alzheimers Dis"},{"key":"BFsrep07771_CR23","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/nrn938","volume":"3","author":"D Schenk","year":"2002","unstructured":"Schenk, D. Amyloid-\u03b2 immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3, 824\u2013828 (2002).","journal-title":"Nat Rev Neurosci"},{"key":"BFsrep07771_CR24","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman, S. et al. Clinical effects of A\u03b2 immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553\u20131562 (2005).","journal-title":"Neurology"},{"key":"BFsrep07771_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jneuroim.2012.09.008","volume":"254","author":"D Lambracht-Washington","year":"2013","unstructured":"Lambracht-Washington, D. et al. A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation A\u03b242 DNA vaccine for Alzheimer disease. J Neuroimmunol 254, 63\u201368 (2013).","journal-title":"J Neuroimmunol"},{"key":"BFsrep07771_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/gt.2009.140","volume":"17","author":"H Davtyan","year":"2010","unstructured":"Davtyan, H. et al. DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther 17, 261\u2013271 (2010).","journal-title":"Gene Ther"},{"key":"BFsrep07771_CR27","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/j.vaccine.2009.10.092","volume":"28","author":"J Jin","year":"2010","unstructured":"Jin, J. et al. An immunotherapeutic treatment against flea allergy dermatitis in cats by co-immunization of DNA and protein vaccines. Vaccine 28, 1997\u20132004 (2010).","journal-title":"Vaccine"},{"key":"BFsrep07771_CR28","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.4049\/jimmunol.1102828","volume":"189","author":"JY Li","year":"2012","unstructured":"Li, J. Y. et al. Regulatory dendritic cells by DNA and plays a critical role in the induction of Caveolin-1-mediated negative signaling protein coimmunization. J Immunol 189, 2852\u20132859 (2012).","journal-title":"J Immunol"},{"key":"BFsrep07771_CR29","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/jgm.1069","volume":"9","author":"J Li","year":"2007","unstructured":"Li, J. et al. Enhanced contraceptive response by co-immunization of DNA and protein vaccines encoding the mouse zona pellucida 3 with minimal oophoritis in mouse ovary. J Gene Med 9, 1095\u20131103 (2007).","journal-title":"J Gene Med"},{"key":"BFsrep07771_CR30","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/jgm.1200","volume":"10","author":"J Li","year":"2008","unstructured":"Li, J. et al. Treatment of autoimmune ovarian disease by co-administration with mouse zona pellucida protein 3 and DNA vaccine through induction of adaptive regulatory T cells. J Gene Med 10, 810\u2013820 (2008).","journal-title":"J Gene Med"},{"key":"BFsrep07771_CR31","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/imm.12103","volume":"139","author":"A Monsonego","year":"2013","unstructured":"Monsonego, A., Nemirovsky, A. & Harpaz, I. CD4 T cells in immunity and immunotherapy of Alzheimer's disease. Immunology 139, 438\u2013446 (2013).","journal-title":"Immunology"},{"key":"BFsrep07771_CR32","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.biocel.2008.12.015","volume":"41","author":"SW Pimplikar","year":"2009","unstructured":"Pimplikar, S. W. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. INT J Biochem Cell Biol 41, 1261\u20131268 (2009).","journal-title":"INT J Biochem Cell Biol"},{"key":"BFsrep07771_CR33","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2174\/138161211795164112","volume":"17","author":"M Menendez-Gonzalez","year":"2011","unstructured":"Menendez-Gonzalez, M., Perez-Pinera, P., Martinez-Rivera, M., Lopez Muniz, A. & Vega, J. A. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials. Curr Pharm Des 17, 508\u2013520 (2011).","journal-title":"Curr Pharm Des"},{"key":"BFsrep07771_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/187152710791012080","volume":"9","author":"DH Cribbs","year":"2010","unstructured":"Cribbs, D. H. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets 9, 207\u2013216 (2010).","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"BFsrep07771_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00429-009-0236-2","volume":"214","author":"T Wisniewski","year":"2010","unstructured":"Wisniewski, T. & Boutajangout, A. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. Brain Struct Funct 214, 201\u2013218 (2010).","journal-title":"Brain Struct Funct"},{"key":"BFsrep07771_CR36","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaut.2007.07.006","volume":"29","author":"JL Pasquali","year":"2007","unstructured":"Pasquali, J. L., Soulas-Sprauel, P., Korganow, A. S. & Martin, T. Auto-reactive B cells in transgenic mice. J Autoimmun 29, 250\u2013256 (2007).","journal-title":"J Autoimmun"},{"key":"BFsrep07771_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1212\/01.WNL.0000148604.77591.67","volume":"64","author":"AJ Bayer","year":"2005","unstructured":"Bayer, A. J. et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64, 94\u2013101 (2005).","journal-title":"Neurology"},{"key":"BFsrep07771_CR38","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.2353\/ajpath.2006.060269","volume":"169","author":"RL Patton","year":"2006","unstructured":"Patton, R. L. et al. Amyloid-\u03b2 peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. AM J Pathol 169, 1048\u20131063 (2006).","journal-title":"AM J Pathol"},{"key":"BFsrep07771_CR39","doi-asserted-by":"crossref","unstructured":"Chen, G. et al. Active \u03b2-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of \u03b2-amyloid. J Neurosci 27 (2007).","DOI":"10.1523\/JNEUROSCI.3710-06.2007"},{"key":"BFsrep07771_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1750-1326-6-18","volume":"6","author":"J Walter","year":"2011","unstructured":"Walter, J. et al. A new role for interferon gamma in neural stem\/precursor cell dysregulation. Mol Neurodegener 6, 18\u201329 (2011).","journal-title":"Mol Neurodegener"},{"key":"BFsrep07771_CR41","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.2353\/ajpath.2009.090059","volume":"175","author":"MA Mastrangelo","year":"2009","unstructured":"Mastrangelo, M. A., Sudol, K. L., Narrow, W. C. & Bowers, W. J. Interferon-\u03b3 differentially affects Alzheimer's disease pathologies and induces neurogenesis in triple transgenic-AD mice. AM J Pathol 175, 2076\u20132088 (2009).","journal-title":"AM J Pathol"},{"key":"BFsrep07771_CR42","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.4049\/jimmunol.1200947","volume":"190","author":"TC Browne","year":"2013","unstructured":"Browne, T. C. et al. IFN-\u03b3 production by amyloid \u03b2\u2013specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's Disease. J Immunol 190, 2241\u20132251 (2013).","journal-title":"J Immunol"},{"key":"BFsrep07771_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/alzrt256","volume":"6","author":"S Wang","year":"2014","unstructured":"Wang, S. et al. A coimmunization vaccine of A\u03b242 ameliorates cognitive deficits without brain inflammation in an Alzheimer's disease model. Alzheimers Res Ther 6, 26 (2014).","journal-title":"Alzheimers Res Ther"},{"key":"BFsrep07771_CR44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/08923970802713470","volume":"31","author":"YZ Yu","year":"2009","unstructured":"Yu, Y. Z., Li, N., Wang, S., Yu, W. Y. & Sun, Z. W. Improved immunogenicity and protective efficacy of a replicon DNA vaccine encoding the Hc domain of botulinum neurotoxin serotype A by electric pulses and protein boosting. Immunopharm Immunot 31, 397\u2013404 (2009).","journal-title":"Immunopharm Immunot"},{"key":"BFsrep07771_CR45","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.nbd.2003.07.005","volume":"14","author":"J Zhang","year":"2003","unstructured":"Zhang, J. et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and \u03b2-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol Dis 14, 365\u2013379 (2003).","journal-title":"Neurobiol Dis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep07771.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep07771","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep07771.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T21:22:04Z","timestamp":1672953724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep07771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,14]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,7,15]]}},"alternative-id":["BFsrep07771"],"URL":"https:\/\/doi.org\/10.1038\/srep07771","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,14]]},"assertion":[{"value":"16 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7771"}}